VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV.VN), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, presented at the American Association of Cancer Research Annual Meeting.
Read more at globenewswire.comInvestmentPitch Media Video Discusses Rakovina Therapeutics and its Presentation of Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research Annual General Meeting
Globe Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/AI%20microchip%20by%20DesignKingBD360%20via%20Shutterstock.jpg)
/2d%20illustration%20of%20Cloud%20computing%20by%20Blackboard%20via%20Shutterstock.jpg)
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)
